Stem cell therapy may have the ability to slow the progression of ALS. This is conducted through stem cells' ability to differentiate into unique types of supportive cells such as astrocytes and microglia (cells within the central nervous system). These supportive cells may have the ability to slow the degeneration of motor neurons within the Central Nervous System (CNS).
April 27, 2021
Apr 27, 2021
Medical Director | DVC Stem
The premise of stem cell therapy for ALS aims to improve the diseased microenvironment. While stem cell transplants are unable to replace diseased motor neurons directly in ALS patients, transplanted stem cells secrete neurotrophic factors and differentiate into supportive cells, such as astrocytes and microglia, generating a neuroprotective milieu that can slow degeneration of motor neurons.
Amyotrophic Lateral Sclerosis, or ALS, is a relatively tricky disease to understand and treat. It affects approximately one to two per 100,000 people in the United States every year.
Nearly 95% of ALS cases are caused by unknown factors, with only around 5% being genetically inherited from parents. Although ALS usually strikes around age 50-60, it can affect people of any age.
Unfortunately, there is no known cure for Amyotrophic Lateral Sclerosis (ALS), and the current prognosis is two to four years from onset. Recent advances in stem cell technology have provided both new tools for researchers to fight ALS, as well as possible new treatments for patients themselves. Stem cell therapy may be able to delay the progression of the disease state. However, more long term research studies should be conducted to establish treatment efficacy.
Amyotrophic Lateral Sclerosis (ALS) occurs when the body starts experiencing the death of neurons controlling voluntary muscles.
ALS affects both upper and lower motor neurons, meaning patients with the disease begin to experience both involuntary spasticity as well as weakening of the muscles over time. This involuntary spasticity results in worsening symptoms.
There are currently drugs available, which both slightly increase length of life, as well as improve quality of life, but there is no accepted cure for ALS today. There has been a push in recent years to raise awareness to ALS in an attempt to promote research into finding a cure. This increase in awareness was most notably seen in 2014 with the introduction of the ALS Ice Bucket Challenge.
Stem cell therapy may be a viable treatment option for ALS. Stem cells may be a viable solution to sustain and nurture diseased motor neurons. (1)
According to Goutman et al.
“The premise of stem cell therapy for ALS aims to improve the diseased microenvironment. While stem cells are unable to replace diseased motor neurons directly, transplanted stem cells secrete neurotrophic factors and differentiate into supportive cells, such as astrocytes and microglia, generating a neuroprotective milieu that can slow degeneration of motor neurons.” (1)
Researchers have turned to stem cells in the fight against ALS for two main reasons.
A study conducted by Panayiota Petrou et al. in 2016, found stem cell therapy to be both safe and well-tolerated by ALS patients.
“Among the 26 patients, 87% were defined as responders to either ALS Functional Rating Scale-Revised or forced vital capacity, having at least 25% improvement at six months after treatment in the slope of progression.” (2)
Researchers hope treatments like this will be able to eventually slow to stop the progression of ALS, vastly improving the results of current drugs on the market.
Stem cell therapy may have the ability to slow the progression of ALS. This is conducted through stem cells ability to differentiate into unique types of supportive cells such as astrocytes and microglia (cells within the central nervous system). These supportive cells may have the ability to slow the degeneration of motor neurons within the CNS.
DVC Stem is a stem cell therapy pioneer, offering stem cell therapies for years and has become a cornerstone of the medical tourism industry. Located in the tropical paradise of Grand Cayman in the Western Caribbean, we offer patients a nearby alternative to travelling long distances and to less ideal locations. Our protocols are IRB approved, and our cells come from regulated, U.S. based, FDA compliant laboratories. We seek to offer the highest quality products, the latest available treatments for a variety of conditions, all combined with a world-class setting and service. Contact us today to request additional information.
(1) Stephen A. Goutman, Masha G. Savelieff, Stacey A. Sakowski & Eva L. Feldman (2019) Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials, Expert Opinion on Investigational Drugs, 28:6, 525-543, DOI: 10.1080/13543784.2019.1627324
(2) Petrou P, Gothelf Y, Argov Z, et al. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. JAMA Neurol. 2016;73(3):337–344. doi:https://doi.org/10.1001/jamaneurol.2015.4321
About the author
Dr. Cona has been performing stem cell therapy for over 10 years. He is a member of the World Academy of Anti-Aging Medicine (WAAAM). He is also a recognized member of the British Medical Association, the General Medical Council (UK), the Caribbean College of Family Physicians, and the American Academy of Family Physicians. He is the Medical Director for DVC Stem a world-renowned stem cell therapy clinic located in Grand Cayman.
Are you a candidate for stem cell treatment?
Complete our brief online application to find out if our IRB-approved mesenchymal stem cell treatment is right for you.Apply for treatment
You might also like...
The borders of the Cayman Islands are in a phased reopening process, which will expand within the next couple of months. This means that the airport is open but travel must be approved by the Cayman Islands Government & all visitors must participate in a mandatory 10 - 14 day quarantine.
Stem cell therapy results have been extremely positive so far, with approximately 75% of Multiple Sclerosis patients reporting significant improvement within 3 months of treatment, and showing little to no signs of regression out to 18-24 months. Our full Multiple Sclerosis study results are expected to be published later this year.
New study has found mesenchymal stem cells to be both a safe and effective treatment option for stroke.
Are people with Multiple Sclerosis more prone to severe Coronavirus related illness? Having a compromised immune system could potentially increase one’s risk of developing severe Coronavirus symptoms. This article aims to answer this question as well as describe the actions MS patients should take to mitigate risk.
Explaining the relationship between stem cell therapy and Parkinson's.
DVC STEM, GRAND CAYMAN